227 related articles for article (PubMed ID: 23898841)
41. Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics.
Machado D; Azzali E; Couto I; Costantino G; Pieroni M; Viveiros M
Future Microbiol; 2018 Sep; 13():1383-1402. PubMed ID: 30259757
[TBL] [Abstract][Full Text] [Related]
42. Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.
Gold B; Smith R; Nguyen Q; Roberts J; Ling Y; Lopez Quezada L; Somersan S; Warrier T; Little D; Pingle M; Zhang D; Ballinger E; Zimmerman M; Dartois V; Hanson P; Mitscher LA; Porubsky P; Rogers S; Schoenen FJ; Nathan C; Aubé J
J Med Chem; 2016 Jul; 59(13):6027-44. PubMed ID: 27144688
[TBL] [Abstract][Full Text] [Related]
43. Derivatives of 3-isoxazolecarboxylic acid esters: a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis.
Lilienkampf A; Pieroni M; Franzblau SG; Bishai WR; Kozikowski AP
Curr Top Med Chem; 2012; 12(7):729-34. PubMed ID: 22283815
[TBL] [Abstract][Full Text] [Related]
44. Inhibiting DosRST as a new approach to tuberculosis therapy.
Zheng H; Abramovitch RB
Future Med Chem; 2020 Mar; 12(5):457-467. PubMed ID: 32053005
[TBL] [Abstract][Full Text] [Related]
45. Benzaldehyde thiosemicarbazone derivatives against replicating and nonreplicating Mycobacterium tuberculosis.
Volynets GP; Tukalo MA; Bdzhola VG; Derkach NM; Gumeniuk MI; Tarnavskiy SS; Starosyla SA; Yarmoluk SM
J Antibiot (Tokyo); 2019 Apr; 72(4):218-224. PubMed ID: 30662064
[TBL] [Abstract][Full Text] [Related]
46. Novel MenA Inhibitors Are Bactericidal against
Berube BJ; Russell D; Castro L; Choi SR; Narayanasamy P; Parish T
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962346
[No Abstract] [Full Text] [Related]
47. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis.
Gold B; Warrier T; Nathan C
Methods Mol Biol; 2015; 1285():293-315. PubMed ID: 25779324
[TBL] [Abstract][Full Text] [Related]
48. Novel Chemical Scaffolds for Inhibition of Rifamycin-Resistant RNA Polymerase Discovered from High-Throughput Screening.
Scharf NT; Molodtsov V; Kontos A; Murakami KS; Garcia GA
SLAS Discov; 2017 Mar; 22(3):287-297. PubMed ID: 28027449
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.
Zhang M; Sala C; Dhar N; Vocat A; Sambandamurthy VK; Sharma S; Marriner G; Balasubramanian V; Cole ST
Antimicrob Agents Chemother; 2014 Jun; 58(6):3217-23. PubMed ID: 24663022
[TBL] [Abstract][Full Text] [Related]
50. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
Sala C; Dhar N; Hartkoorn RC; Zhang M; Ha YH; Schneider P; Cole ST
Antimicrob Agents Chemother; 2010 Oct; 54(10):4150-8. PubMed ID: 20679505
[TBL] [Abstract][Full Text] [Related]
51. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.
Ballell L; Bates RH; Young RJ; Alvarez-Gomez D; Alvarez-Ruiz E; Barroso V; Blanco D; Crespo B; Escribano J; González R; Lozano S; Huss S; Santos-Villarejo A; Martín-Plaza JJ; Mendoza A; Rebollo-Lopez MJ; Remuiñan-Blanco M; Lavandera JL; Pérez-Herran E; Gamo-Benito FJ; García-Bustos JF; Barros D; Castro JP; Cammack N
ChemMedChem; 2013 Feb; 8(2):313-21. PubMed ID: 23307663
[TBL] [Abstract][Full Text] [Related]
52. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Cho SH; Warit S; Wan B; Hwang CH; Pauli GF; Franzblau SG
Antimicrob Agents Chemother; 2007 Apr; 51(4):1380-5. PubMed ID: 17210775
[TBL] [Abstract][Full Text] [Related]
53. Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis.
Rakesh ; Bruhn DF; Scherman MS; Woolhiser LK; Madhura DB; Maddox MM; Singh AP; Lee RB; Hurdle JG; McNeil MR; Lenaerts AJ; Meibohm B; Lee RE
PLoS One; 2014; 9(2):e87909. PubMed ID: 24505329
[TBL] [Abstract][Full Text] [Related]
54. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.
Zhang M; Sala C; Hartkoorn RC; Dhar N; Mendoza-Losana A; Cole ST
Antimicrob Agents Chemother; 2012 Nov; 56(11):5782-9. PubMed ID: 22926567
[TBL] [Abstract][Full Text] [Related]
55. InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.
Flint L; Korkegian A; Parish T
PLoS One; 2020; 15(11):e0239354. PubMed ID: 33201882
[TBL] [Abstract][Full Text] [Related]
56. Discovery of new
Mehra R; Chib R; Munagala G; Yempalla KR; Khan IA; Singh PP; Khan FG; Nargotra A
Mol Divers; 2015 Nov; 19(4):1003-19. PubMed ID: 26232029
[TBL] [Abstract][Full Text] [Related]
57. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
Urban M; Šlachtová V; Brulíková L
Eur J Med Chem; 2021 Feb; 212():113139. PubMed ID: 33422979
[TBL] [Abstract][Full Text] [Related]
58. Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.
Siricilla S; Mitachi K; Wan B; Franzblau SG; Kurosu M
J Antibiot (Tokyo); 2015 Apr; 68(4):271-8. PubMed ID: 25269459
[TBL] [Abstract][Full Text] [Related]
59. In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
Solapure S; Dinesh N; Shandil R; Ramachandran V; Sharma S; Bhattacharjee D; Ganguly S; Reddy J; Ahuja V; Panduga V; Parab M; Vishwas KG; Kumar N; Balganesh M; Balasubramanian V
Antimicrob Agents Chemother; 2013 Jun; 57(6):2506-10. PubMed ID: 23507276
[TBL] [Abstract][Full Text] [Related]
60. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
